Candriam S.C.A. - GLOBAL BLOOD THERAPEUTICS IN ownership

GLOBAL BLOOD THERAPEUTICS IN's ticker is GBT and the CUSIP is 37890U108. A total of 259 filers reported holding GLOBAL BLOOD THERAPEUTICS IN in Q2 2020. The put-call ratio across all filers is 0.93 and the average weighting 0.2%.

Quarter-by-quarter ownership
Candriam S.C.A. ownership history of GLOBAL BLOOD THERAPEUTICS IN
ValueSharesWeighting
Q3 2022$24,582,000
-1.3%
360,956
-53.7%
0.17%
-15.6%
Q2 2022$24,910,000
-5.0%
779,691
+3.0%
0.20%
+15.2%
Q1 2022$26,211,000
+38.1%
756,708
+16.7%
0.18%
+47.1%
Q4 2021$18,977,000
+123.0%
648,339
+94.1%
0.12%
+108.6%
Q3 2021$8,511,000
+23.8%
334,041
+70.1%
0.06%
+23.4%
Q2 2021$6,875,000
+60.5%
196,330
+189.4%
0.05%
+4.4%
Q2 2020$4,283,000
+22.5%
67,843
+50.8%
0.04%
+15.4%
Q1 2020$3,497,000
-2.2%
45,0000.0%0.04%
+2.6%
Q4 2019$3,577,000
-9.2%
45,000
-53.1%
0.04%
-37.7%
Q4 2018$3,941,000
-36.8%
96,000
-41.5%
0.06%
-26.5%
Q3 2018$6,232,000
+51.5%
164,000
+80.2%
0.08%
+27.7%
Q2 2018$4,113,000
+10.6%
91,000
+18.2%
0.06%
+3.2%
Q1 2018$3,719,000
-11.7%
77,000
-28.0%
0.06%
-13.7%
Q4 2017$4,210,000
+39.8%
107,000
+10.3%
0.07%
+37.7%
Q3 2017$3,012,000
+32.7%
97,000
+16.9%
0.05%
+23.3%
Q2 2017$2,270,000
-20.0%
83,000
+7.8%
0.04%
-21.8%
Q1 2017$2,838,000
+155.0%
77,0000.0%0.06%
+111.5%
Q4 2016$1,113,000
-19.5%
77,000
+28.3%
0.03%
-21.2%
Q3 2016$1,383,000
+138.0%
60,000
+71.4%
0.03%
+120.0%
Q2 2016$581,00035,0000.02%
Other shareholders
GLOBAL BLOOD THERAPEUTICS IN shareholders Q2 2020
NameSharesValueWeighting ↓
Alerce Investment Management, L.P. 356,270$24,262,00023.36%
Twin Securities, Inc. 376,669$25,651,00011.94%
Paradigm Biocapital Advisors LP 1,175,879$80,077,00010.68%
Chicago Capital Management, LLC 246,246$16,769,0009.12%
HARVEST MANAGEMENT LLC 141,500$9,636,0007.78%
Fernwood Investment Management, LLC 174,724$11,899,0005.02%
ArchPoint Investors 168,725$11,490,0004.69%
HAVENS ADVISORS LLC 46,000$3,133,0004.69%
Perceptive Advisors 2,322,247$158,145,0004.59%
Crabel Capital Management, LLC 112,680$7,674,0004.48%
View complete list of GLOBAL BLOOD THERAPEUTICS IN shareholders